Clinical Characteristics and Risk Factors for Nosocomial Candidemia in Medical Intensive Care Units: Experience in a Single Hospital in Korea for 6.6 Years

The aim of this study was to determine candidemia incidence among patients in a medical intensive-care unit (MICU) and the associated mortality rate and to identify risk factors associated with candidemia. We retrospectively performed a 1:3 matched case-control study of MICU patients with candidemia. Controls were matched for sex, age, and Acute Physiology and Chronic Health Evaluation (APACHE) II score. Candidemia incidence was 9.1 per 1,000 admissions. The most common pathogen was *Candida albicans*. Crude mortality was 96% among candidemia patients and 52% among controls (P<0.001). Mortality differed significantly between the groups according to Kaplan-Meier survival analysis (P=0.024). Multivariate analysis identified the following independent risk factors for candidemia: central venous catheterization (odds ratio [OR] = 3.2, 95% confidence interval [CI]=1.2-9.0), previous steroid therapy (OR=4.7, 95% CI=1.8-12.1), blood transfusion during the same admission period (OR=6.3, 95% CI=2.4-16.7), and hepatic failure upon MICU admission (OR=6.9, 95% CI=1.7-28.4). In conclusion, we identify an additional independent risk factor for candidemia, the presence of hepatic failure on MICU admission. Therefore, increased awareness of risk factors, including hepatic failure, is necessary for the management of candidemia.

Key Words: Fungemia; Candidiasis; Intensive-Care Units; Mortality; Risk Factors

INTRODUCTION

The incidence of bloodstream infections with fungi (especially *Candida* species) has increased substantially during recent decades (1). One study revealed that the incidence of candidemia increased from 1.25 episodes per 10,000 patient days per year in 1999 to 3.06 episodes per 10,000 patient days per year in 2003 (2). In the United States, *Candida* species are the fourth highest cause of nosocomial bloodstream infection (3). Moreover, the overall mortality of patients with a blood culture positive for *Candida* species ranges from 31% to 81% (4-11).

Although antifungal agents have recently been developed and are widely used, the incidence of candidemia and its associated mortality are increasing, especially in patients with severe underlying diseases (12). This trend is associated with an increase in the number of patients who receive immunosuppressive agents after antineoplastic or antirejection chemotherapy (13, 14). The known risk factors for candidemia are immunosuppression, neutropenia, hemodialysis, long-term use of a central venous catheter, previous broad-spectrum antibiotic use, and *Candida* colonization (1, 13). As these risk factors are common among intensive-care unit (ICU) patients, ICUs are high-risk environments for candidemia.

There are few recent studies on the epidemiology of candidemia in medical ICUs (MICUs). Therefore, we undertook a case-control study of MICU patients to evaluate their clinical characteristics, including the incidence of candidemia, the predominant infectious organisms present, mortality, and risk factors for candidemia in an MICU.

MATERIALS AND METHODS

Study design and patients

We performed a retrospective 1:3 matched case-control study. The study was conducted at the Seoul National Univer-
Definitions

Nosocomial candidemia was defined as one or more blood cultures positive for *Candida* species at least 48 hr after admission. Blood cultures were tested routinely if a patient’s temperature was greater than 38°C. The onset of candidemia was defined as the date on which the first positive blood culture was detected. In-hospital mortality was defined as death during the same period of hospitalization.

Hemodynamic instability was defined as systolic blood pressure (BP) <90 mmHg, diastolic BP <60 mmHg, mean arterial pressure (BP) <70 mmHg, or administration of a vasopressor to the ICU. Patients were considered as having neutropenia if their absolute neutrophil count was <500 cells/mm³ on admission to the ICU. Acute renal failure was defined as a 0.5 mg/dL increase in serum creatinine level on admission to the ICU. Hepatic failure was defined as aspartate aminotransferase (AST) level >200 IU/L, alanine aminotransferase (ALT) level >200 IU/L, albumin level <3.0 g/dL, and prothrombin INR >2.0 on admission to the ICU. Acute renal failure was defined as a 0.5 mg/dL increase in serum creatinine level on admission to the ICU. Acute renal failure was defined as a 0.5 mg/dL increase in serum creatinine level on admission to the ICU. Acute renal failure was defined as a 0.5 mg/dL increase in serum creatinine level on admission to the ICU. Acute renal failure was defined as a 0.5 mg/dL increase in serum creatinine level on admission to the ICU. Acute renal failure was defined as a 0.5 mg/dL increase in serum creatinine level on admission to the ICU. Acute renal failure was defined as a 0.5 mg/dL increase in serum creatinine level on admission to the ICU. Acute renal failure was defined as a 0.5 mg/dL increase in serum creatinine level on admission to the ICU.
candidemia in 20 patients (41%). Various causative organisms of bacteremia were detected: Clostridium perfringens, Escherichia coli, Enterobacter cloacae, Enterococcus faecium, Klebsiella pneumoniae, Staphylococcus aureus, Pseudomonas aeruginosa, and Staphylococcus epidermidis. The median duration of antibiotic use before the onset of candidemia was 16 days (range, 1-92 days). All patients were treated with antibiotics before the onset of candidemia.

Comparison of candidemia patients with matched control patients

There were no significant differences in demographic characteristics or underlying diseases between the candidemia patients and the controls, except for the presence of malignancy (Table 1). Malignancy was more prevalent in patients with candidemia than in the control patients (P=0.048). This difference was not associated with solid malignancies (12 candidemia patients [25%] vs. 35 control patients [24%]; P=0.923) but with hematological malignancies (18 candidemia patients [37%] vs. 31 control patients [21%]; P=0.028). The dialysis method used for patients with chronic renal failure did not differ between the 2 groups. Patients with candidemia had longer stays in hospital and in the MICU compared with the control group, but there was no difference in their pre-ICU hospital stays (Table 1). Patients with candidemia were mechanically ventilated for a longer period during their total MICU stay than the controls (P=0.001) and had a longer MICU stay than the controls (P=0.001). At the time of MICU admission, patients with candidemia were more hemodynamically unstable than the controls (P<0.001).

Univariate analysis identified 8 variables that differed significantly between the candidemia patients and the controls (Table 2). These were central venous catheterization, candida colonization, an immunocompromised state, previous steroid therapy, transfusion, TPN, hepatic failure, and neutropenia on MICU admission. Multivariate analysis of these 8 vari-

### Table 1. Baseline characteristics of patients with candidemia and controls in an MICU

| Characteristics                  | Candidemia patients (n=49) | Controls (n=147) |
|----------------------------------|---------------------------|------------------|
| **Underlying illness**           |                           |                  |
| COPD, No. (%)                    | 0 (0)                     | 5 (3)            |
| Malignancy*, No. (%)             | 30 (61)                   | 66 (45)          |
| Diabetes, No. (%)                | 15 (31)                   | 42 (29)          |
| Congestive heart failure, No. (%)| 4 (8)                     | 18 (12)          |
| Hypertension, No. (%)            | 14 (29)                   | 41 (28)          |
| Ischemic heart disease, No. (%)  | 5 (10)                    | 22 (15)          |
| Cerebral infarct, No. (%)        | 6 (12)                    | 17 (12)          |
| Chronic renal failure, No. (%)   | 8 (16)                    | 20 (14)          |
| Chronic liver disease, No. (%)   | 4 (8)                     | 22 (15)          |
| Transplantation, No. (%)         | 4 (8)                     | 11 (7)           |
| Adrenal insufficiency, No. (%)   | 5 (10)                    | 5 (3)            |
| Operation during same admission, No. (%) | 8 (16) | 18 (12) |
| Total duration of hospital stay (days), median (range) | 38 (2-141) | 25 (2-335) |
| Total duration of ICU stay (days), median (range) | 22 (1-141) | 8 (1-119) |
| Duration of pre-ICU stay (days), median (range) | 8 (0-92) | 1 (0-260) |
| Total duration of ventilator use (days), median (range) | 19 (0-139) | 7 (0-119) |
| Duration of precandidemia ICU stay (days), median (range) | 17 (0-117) | - |
| Duration of antifungal therapy (days), median (range) | 11 (1-45) | - |
| Delay in commencement of therapy (days), median (range) (n=28) | 2 (0-7) | - |
| Patients with preemptive therapy, No. (%) | 8 (16) | - |
| Hemodynamic instability on admission to the ICU, No. (%) | 46 (94) | 94 (64) |

*P<0.05 for candidemia patients vs. controls according to the chi-square test. **P<0.05 for candidemia patients vs. controls according to the Mann-Whitney test.

APACHE, Acute Physiology and Chronic Health Evaluation; COPD, chronic obstructive pulmonary disease; ICU, intensive-care unit; duration of pre-ICU stay, general ward stay before ICU admission; duration of precandidemia ICU stay, days from ICU admission to candidemia; delay in start of therapy, days from diagnosis of candidemia to commencement of antifungal therapy; patients with preemptive therapy, patients treated with antifungal therapy before candidemia was diagnosed.
ables using logistic regression revealed that central venous catheterization, previous steroid therapy, transfusion during the same admission, and hepatic failure on MICU admission were independent risk factors for candidemia (Table 3).

In-hospital mortality was 96% (47 of 49 patients) for patients with candidemia and 52% (77 of 147 patients) for control patients with odds ratio (OR) 21.4 (95% confidence interval [CI] 5.0-91.2). The significance of this difference in mortality rate was confirmed using Kaplan-Meier survival curves ($P=0.024$; Fig. 1).

**DISCUSSION**

We performed a 1:3 matched case-control study to determine the incidence of candidemia in MICU patients and the mortality rate among these patients to identify factors associated with candidemia. We matched cases and controls on admission using variables known to be strongly correlated with nosocomial infections and the risk of death (e.g., severe illness and age). There were no differences between cases and controls in underlying illnesses, except for malignancy. The duration of the pre-ICU hospital stay did not differ significantly between groups.

In our study, the incidence of candidemia (9.1 patients per 1,000 admissions) and the crude mortality rate (96%) of candidemia patients were greater than those of previous studies, in which the incidence of candidemia was 0.3-2.5 episodes per 1,000 admissions (4, 7, 12, 17) and the crude mortality rate was 31-61% (4-9). Lee et al. (18) reported that the incidence of candidemia in a Korean ICU was 0.3-1.5 episodes per 1,000 patient days and that the crude mortality was 48.3%. This discrepancy may have arisen because we included patients with severe disease and only enrolled MICU patients with a pre-existing risk factor for candidemia. Our study involved more patients with malignancy (61%) than previous studies (10-41%) (4, 5, 9, 18), which may also have contributed to the relatively high incidence of candidemia in our study.

Attributable mortality in our study was 44% (96% minus 52%), which is similar to the results of previous studies (34-49%). However, crude mortality was higher in our study than in previous studies (96% vs. 40-61%, respectively) (5, 9, 12, 18, 19). Of 8 patients who received preemptive antifungal therapy, only 1 survived. There are several potential explanations for the difference in crude mortality between our study and previous studies. First, criteria for enrollment in our study were stricter than those of other studies, which enrolled general ward patients whose mortality rate was lower than that of our patients (5, 9, 19). According to previous studies, an APACHE II score >20 during candidemia is associated with an elevated mortality rate (12) irrespective of intensive antifungal therapy (15). For this reason, we conducted an APACHE II score-matched case-control study. This matching procedure ensures that the control group is valid for comparison of mortality rate. Second, our study included more patients with malignancy (61%) than previous studies (10-41%) (4, 5, 9, 18). These factors may have been responsible for the high mortality rate in our study.

The Kaplan-Meier survival analysis showed that the difference in mortality between the two groups was sustained ($P=0.024$). In terms of underlying illness, the candidemia patients had more malignancies than the control patients ($P=0.048$). Therefore, it could be inferred that the difference in the prevalence of malignancy contributed to the difference in mortality. However, survival analysis that excluded patients with a hematological malignancy showed a consistent result ($P=0.037$ according to the log-rank test).

Many studies have been undertaken to evaluate risk factors for the development of candidemia. However, most studies were undertaken using specific patient populations or did not use case-control methodology (4, 10). Using a case-control design, we identified several independent risk factors for candidemia in the MICU: central venous catheterization, previous steroid therapy, and previous transfusion. This result is consistent with risk factors identified by other authors (5, 13, 20, 21).

We identified a new risk factor, viz., the presence of hepatic
failure on admission to the MICU. A previous study reported that fungal infection (predominantly candidiasis) is a common complication (32%) in patients with acute liver failure (22). However, there are few reports on hepatic failure as an independent risk factor for candidemia. In our study, 9 patients in the candidemia group had hepatic failure on admission to the MICU. Using multivariate analysis, we identified hepatic failure on admission to the MICU as an independent risk factor for candidemia (OR, 7.6; 95% CI, 1.5-39.0). Hepatic failure may be a risk factor because patients with hepatic failure have increased susceptibility to infection because of abnormal immune function (23), increased colonization of the small bowel (24, 25), impaired phagocytic function (26, 27), or reduced complement levels (28).

Our study has several limitations. First, the incidence of candidemia in the MICU might have been underestimated. Because this was a retrospective study, no specific fungal blood cultures were performed. In our hospital, blood is cultured for 5 days using a Bact/Alert 3D instrument (BioMerieux, Inc., Durham, NC, USA) when a routine blood culture is requested. However, if a fungal blood culture is requested, the blood is cultured for 3 weeks to identify any slow-growing Candida species. Several authors have reported that they cultured blood for more than 5 days to identify specific slow-growing organisms. Therefore, it has been suggested that the appropriate duration for blood culture should be determined on an individual basis according to the clinical relevance of the culture (29, 30). A prospective study would have avoided this methodological weakness.

Second, the control patients had no evidence of bacterial or fungal growth in their blood cultures. However, systemic bacterial or fungal infections may be present even if blood cultures are negative. In this study, 67 patients (46%) in the control group used empirical antibiotics. Therefore, the control group may have included infected patients. However, circumvention of this situation is clinically very difficult. Therefore, we performed a multivariate analysis that included antibiotic use as a variable.

In conclusion, bloodstream Candida infections in MICUs are associated with much higher crude mortality rates than would be expected for uninfected patients with the same disease severity. We identify an additional independent risk factor for candidemia, the presence of hepatic failure on MICU admission. Therefore, increased awareness of risk factors, including hepatic failure, is necessary for the management of candidemia.

ACKNOWLEDGEMENTS

We thank Professor Eui Chong Kim of the Department of Laboratory medicine for his approval and support for this work. We are grateful to the doctors and nurses of medical intensive-units; the medical records officer of Seoul National University Hospital. All authors have no financial support.

REFERENCES

1. Eggimann P, Garbino J, Pittet D. Epidemiology of Candida species infections in critically ill non-immunosuppressed patients. Lancet Infect Dis 2003; 3: 685-702.
2. Bassetti M, Righi E, Costa A, Fasce A, Molinari MP, Rosso R, Pallavicini FB, Viscoli C. Epidemiological trends in nosocomial candidemia in intensive care. BMC Infect Dis 2007; 6: 21.
3. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004; 39: 309-17.
4. Klingspor L, Tornqvist E, Johansson A, Petrinii B, Forsum U, Hedin G. A prospective epidemiological survey of candidaemia in Sweden. Scand J Infect Dis 2004; 36: 52-5.
5. Puzniak L, Teutsch S, Powderly W, Polish L. Has the epidemiology of nosocomial candidemia changed? Infect Control Hosp Epidemiol 2004; 25: 628-33.
6. Morgan J, Meltzer MI, Plikaytis BD, Sofair AN, Huei-White S, Wilcox S, Harrison LH, Seaberg EC, Hajjeh RA, Teutsch SM. Excess mortality, hospital stay, and cost due to candidemia: a case control study using data from population-based candidemia surveillance. Infect Control Hosp Epidemiol 2005; 26: 540-7.
7. Alonso-Valle H, Acha O, Garcia-Palomino JD, Farinas-Alvarez C, Fernandez-Mazarrasa C, Farinas MC. Candidemia in a tertiary care hospital: epidemiology and factors influencing mortality. Eur J Clin Microbiol Infect Dis 2003; 22: 254-7.
8. Jamal WY, El-Din K, Rotimi VO, Chugh TD. An analysis of hospital-acquired bacteremia in intensive care unit patients in a university hospital in Kuwait. J Hosp Infect 1999; 43: 49-56.
9. Gudlaugsson O, Gillespie S, Lee K, Vande Berg J, Hu J, Messer S, Herwaldt L, Pfaller M, Diekema D. Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis 2003; 37: 1172-7.
10. Nieto-Rodriguez JA, Kusne S, Manez R, Irish W, Linden P, Magnone M, Wing EJ, Fung JJ, Starzl TE. Factors associated with the development of candidemia and candidemia-related death among liver transplant recipients. Ann Surg 1996; 223: 70-6.
11. McNeil MM, Nash SL, Hajjeh RA, Phelan MA, Conn LA, Plikaytis BD, Warnock DW. Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997. Clin Infect Dis 2001; 33: 641-7.
12. Nolla-Salas J, Stiges-Serra J, Leon-Gil C, Martinez-Gonzalez J, Leon-Regidor MA, Ibanez-Lucia P, Torres-Rodriguez JM. Candidemia in non-neutropenic critically ill patients: analysis of prognostic factors and assessment of systemic antifungal therapy. Intensive Care Med 1997; 23: 23-30.
13. Vincent JL, Annaisse E, Bruning H, Demajo W, el-Ebary M, Haber J, Hiramiatsu Y, Nitenberg G, Nystrom PO, Pittet D, Rogers T, Sandven P, Sanga G, Schaller MD, Solomkin J. Epidemiology, diagnosis, and treatment of systemic Candida infection in surgical patients.
under intensive care. Intensive Care Med 1998; 24: 206-16.
14. Herbrecht R. Managing the challenges of invasive fungal infections. Int J Antimicrob Agents 2006; 27 (Suppl 1): 1-2.
15. Rex JH, Pappas PG, Karchner AW, Sobel J, Edwards JE, Hadley S, Brass C, Vazquez IA, Chapman SW, Horowitz HW, Zervos M, McKinsey D, Lee J, Babincak T, Bradsher RW, Cleary JD, Cohen DM, Danziger L, Goldman M, Goodman J, Hilton E, Hyslop NE, Kett DH, Lutz J, Rubin RH, Scheld WM, Schuster M, Simmons B, Stein DK, Washburn RG, Mautner L, Chu TC, Panzer H, Rosenberg RB, Booth J; National Institute of Allergy and Infectious Diseases Mycoses Study Group. A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. Clin Infect Dis 2003; 36: 1221-8.
16. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med 1985; 13: 818-29.
17. Blot SI, Vandewoude KH, Hoste EA, Colardyn FA. Effects of nosocomial candidemia on outcomes of critically ill patients. Am J Med 2002; 113: 480-5.
18. Lee YH, Choi JJ, Lee MA. Risk factors for the development of nosocomial candidemia among patients in intensive care unit. Infect Chemother 2004; 36: 219-26.
19. Wey SB, Mori M, Pfaller MA, Woolson RF, Wenzel RP. Hospital-acquired candidemia. The attributable mortality and extra length stay. Arch Intern Med 1998; 148: 2642-5.
20. Maschmeyer G. The changing epidemiology of invasive fungal infections: new threats. Int J Antimicrob Agents 2006; 27 (Suppl 1): 3-6.
21. Falagas ME, Apostolou KE, Pappas VD. Attributable mortality of candidemia: a systematic review of matched cohort and case control studies. Eur J Clin Microbiol Infect Dis 2006; 25: 419-25.
22. Rolando N, Harvey F, Brahm J, Phlipott-Howard J, Alexander G, Casewell M, Fagan E, Williams R. Fungal infection: a common, unrecognized complication of acute liver failure. J Hepatol 1991; 12: 1-9.
23. Rolando N, Phlipott-Howard J, Williams R. Bacterial and fungal infection in acute liver failure. Semin Liver Dis 1996; 16: 389-402.
24. Chang CS, Chen GH, Lien HC, Yeh HZ. Small intestine dysmotility and bacterial overgrowth in cirrhotic patients with spontaneous bacterial peritonitis. Hepatology 1998; 28: 1187-90.
25. Fisher NC, Cooper MA, Hastings JG, Mutimer DJ. Fungal colonisation and fluconazole therapy in acute liver disease. Liver 1998; 18: 320-5.
26. Gomez F, Ruiz P, Schreiber AD. Impaired function of macrophage Fc? receptors and bacterial infection in alcoholic cirrhosis. N Engl J Med 1994; 331: 1122-8.
27. Guarner C, Runyon BA. Macrophage function in cirrhosis and the risk of bacterial infection. Hepatology 1995; 22: 367-9.
28. Homann C, Varming K, Hogasen K, Mollnes TE, Graudal N, Thomsen AC, Garred P. Acquired C3 deficiency in patients with alcoholic cirrhosis predisposes to infection and increased mortality. Gut 1997; 40: 544-9.
29. Reisner BS, Woods GL. Times to detection of bacteria and yeasts in BACTEC 9240 blood culture bottles. J Clin Microbiol 1999; 37: 2024-6.
30. Saito T, Senda K, Takakura S, Fujihara N, Kudo T, Finuma Y, Tanimoto M, Ichiyama S. Detection of bacteria and fungi in BacT/Alert standard blood-culture bottles. J Infect Chemother 2003; 9: 227-32.